Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASLOral presentation will ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Wednesday it would ...
A silent health crisis may be developing inside your body without any obvious warning signs. Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease ...
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ...
Please provide your email address to receive an email when new articles are posted on . Alcoholic liver disease and MASH were the most common indications for liver transplantation in candidates ...
Hosted on MSN
MASH vs. NASH: What the name change means for you
MASH is the updated term for NASH to decrease stigma and improve understanding. The name change links liver disease to metabolic factors, which improves diagnosis and treatment. Challenges include ...
Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the ...
Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...
Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...
IVA is a high-risk, high-reward biotech stock hinging on lanifibranor’s Phase 3 NATiV3 MASH readout by Q4 2026. Click here to ...
MASH patients exhibit a higher spleen-to-liver stiffness ratio than ALD patients, indicating a presinusoidal component in portal hypertension. The study found that MASH patients have larger spleen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results